NaturalProductMech

trinactin

naturalproductmech:mibig-b9a7d2946a MINTED SEEDED cytotoxicenzyme inhibitor

Structure

Standard InChIKeyDFQMKYUSAALDDY-MQEBUAKTSA-N
SMILESCC[C@@H]1C[C@H]2CC[C@H](O2)[C@@H](C(=O)O[C@H](C[C@@H]3CC[C@@H](O3)[C@H](C(=O)O[C@@H](C[C@H]4CC[C@H](O4)[C@@H](C(=O)O[C@H](C[C@@H]5CC[C@@H](O5)[C@H](C(=O)O1)C)CC)C)CC)C)C)C
Stereochemistryfully defined
Cross-referencespubchem:169021

Filing pathway

Polyketides — computed by NPClassifier npclassifier.gnps2.org@2026-09-07, which is why it is pinned rather than recomputed. The gene cluster's asserted class is pks, from MIBiG.

Producer organisms 2

A claim that this taxon makes the compound. The basis says what the evidence addressed — a knockout and a database assertion are not the same claim.

TaxonBasisClusterEvidence
Streptomyces griseus subsp. griseus
NCBITaxon:67263
SOURCE_ASSERTION mibig:BGC0000243 PMID:10858335
Streptomyces griseus subsp. griseus
NCBITaxon:67263
SOURCE_ASSERTION mibig:BGC0000244 PMID:10858335

Occurrences 4

Somebody found the compound in this organism and cited it. That is not a claim that the organism makes it, and nothing here promotes one to the other.

TaxonSourceReference
Streptomyces
NCBITaxon:1883
LOTUS DOI:10.1002/HLCA.19620450227
Streptomyces globisporus
NCBITaxon:1908
LOTUS DOI:10.1007/BF02884062
Streptomyces griseus
NCBITaxon:1911
LOTUS DOI:10.1039/P19880001719
Streptomyces araujoniae
NCBITaxon:544311
LOTUS DOI:10.1094/PHYTO-11-13-0327-R

Biosynthetic gene clusters 2

AccessionHostLocus evidenceGenome
mibig:BGC0000243 Streptomyces griseus subsp. griseus
NCBITaxon:67263
CLUSTER_UNSTATED genbank:AF263011.1
mibig:BGC0000244 Streptomyces griseus subsp. griseus
NCBITaxon:67263
CLUSTER_UNSTATED genbank:AF263012.1

A locus claim and a taxon claim are different questions. Heterologous expression settles the first and leaves the second where the isolation report left it.

Bioactivities 25

AssayResultReference
Constitutive androstane receptor (CAR) small molecule agonists, cell-based qHTS assay in HepG2 cells4.8517 uMpubchem.aid:2202728
Constitutive androstane receptor (CAR) small molecule agonists, cell-based qHTS assay in HepG2 cells4.8517 uMpubchem.aid:2202728
GF-AFC viability counterscreen for inhibitors of alpha-synuclein gene (SNCA) expression0.0063 uMpubchem.aid:1671193
P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen0.9677 uMPMID:31515284
Primary fluorescence-based thiol-reactive (MSTI) qHTS assay for identification of artifact compounds.8.899 uMpubchem.aid:1845221
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an RCH-ACV wild type WT cells (2C)0.0136 uMpubchem.aid:1645877
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an RCH-ACV wild type WT cells (2C)0.0136 uMpubchem.aid:1645877
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an isogenic RCH-ACV NSD2 p.E1099K mutant (9B)0.0108 uMpubchem.aid:1645876
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an isogenic RCH-ACV NSD2 p.E1099K mutant (9B)0.0108 uMpubchem.aid:1645876
Primary qHTS to identify anti-liver cancer compounds using libraries of approved drugs and bioactive compounds0.2818 uMpubchem.aid:2202548
Viability qHTS for spleen associated tyrosine kinase inhibitor (SYKi) drug resistant MV4-11 cells0.0137 uMpubchem.aid:1963824
Viability qHTS for spleen associated tyrosine kinase inhibitor (SYKi) drug resistant MV4-11 cells0.0137 uMpubchem.aid:1963824
Viability qHTS for spleen associated tyrosine kinase inhibitor (SYKi) naive MV4-11 cells0.0122 uMpubchem.aid:1963823
Viability qHTS for spleen associated tyrosine kinase inhibitor (SYKi) naive MV4-11 cells0.0122 uMpubchem.aid:1963823
Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput ScreeningACTIVEPMID:31498718
P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screenACTIVEPMID:31515284
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compoundsACTIVEpubchem.aid:1345084

Open questions 1

shared-structure — This structure is reported by more than one MIBiG entry: BGC0000243, BGC0000244. Confirm they describe the same compound rather than an upstream cross-reference error.

Provenance

Source conceptSourceVersion
BGC0000243MIBIG4
BGC0000244MIBIG4

This page is generated from data/natural_products/polyketides/trinactin.yaml, which is generated from the committed inventories. Neither is edited by hand.